References
- UK Government. Coronavirus in the UK: cases in the United Kingdom; 2022 [updated 2022 Apr 21; 2022 Apr 22]. Available from: https://coronavirus.data.gov.uk/details/cases
- Office for National Statistics (UK). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK; 2022 May 6 [updated May 6, 2022]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6may2022
- UK Government. Coronavirus (COVID-19) in the UK: healthcare in the United Kingdom; 2022 Apr 22. Available from: https://coronavirus.data.gov.uk/details/healthcare
- UK Government. Coronavirus (COVID-19) in the UK: deaths in United Kingdom; 2022 [updated 2022 Apr 21; 2022 Apr 22]. Available from: https://coronavirus.data.gov.uk/details/deaths
- UK National Health Service. Reducing burden and releasing capacity to manage the COVID-19 pandemic; 2021. Available from: https://www.england.nhs.uk/coronavirus/documents/reducing-burden-and-releasing-capacity-to-manage-the-c-19-pandemic/
- NHS Confederation & NHS Providers. A reckoning: the continuing cost of COVID-19. 2021 [cited 2022 April 22]. Available from: https://www.nhsconfed.org/sites/default/files/2021-09/A-reckoning-continuing-cost-of-COVID-19.pdf.
- Barber S, Brown J, Ferguson D. Coronavirus: lockdown laws. London (UK): House of Commons; 2021. Available from: https://commonslibrary.parliament.uk/research-briefings/cbp-8875/
- Brown J, Kirk-Wade E. Coronavirus: a history of ‘Lockdown laws’ in England. London (UK): House of Commons; 2021. Available from: https://commonslibrary.parliament.uk/research-briefings/cbp-9068/
- UK Government. Social distancing review: report. London (UK): UK Government; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/999413/Social-Distancing-Review-Report.pdf
- Baraniuk C. Covid-19: how the UK vaccine rollout delivered success, so far. BMJ. 2021;372:n421.
- Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022. DOI:10.1016/S1473-3099(22)00320-6
- Public Health England. Duration of protection of Covid-19 vaccines against clinical disease. London (UK): UK Government; 2021. Available from: https://www.gov.uk/government/publications/phe-duration-of-protection-of-covid-19-vaccines-against-clinical-disease-9-september-2021
- Katikireddi SV, Cerqueira-Silva T, Vasileiou E, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet. 2022;399(10319):25–35.
- Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831–837.
- Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757–773.
- Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. London (UK): Public Health England; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf
- Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2462.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594.
- Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections [pre-print]. medRxiv 2021. DOI:10.1101/2021.08.18.21262237
- JCVI. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022 [Internet]; London (UK): UK Government; 2021 [cited 2022 April 21]. Available from: https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022
- JCVI. Update to JCVI advice on booster vaccination in adults, 2021 [Internet]. London (UK): UK Government. Available from: https://www.gov.uk/government/publications/covid-19-booster-vaccine-programme-for-winter-2021-to-2022-jcvi-statement-november-2021/update-to-jcvi-advice-on-booster-vaccination-in-adults-15-november-2021
- JCVI advice on COVID-19 booster vaccines for those aged 18 to 39 and a second dose for ages 12 to 15 [Internet]; 2021 Nov 29. Available from: https://www.gov.uk/government/news/jcvi-advice-on-covid-19-booster-vaccines-for-those-aged-18-to-39-and-a-second-dose-for-ages-12-to-15
- UK Government. Estimated COVID-19 administrative vaccine uptake of UK population aged 18 and over. London (UK): UK Government; 2022 Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1048360/vaccine-uptake-18-and-over-19-January-2022.ods
- UK Government. Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]; 2021. London (UK): UK Government. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting#yellow-card-reports
- Office for National Statistics (UK). Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid2020 [Internet]; 2021. London (UK): UK Government. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020
- Bjørnstad ON, Shea K, Krzywinski M, et al. The SEIRS model for infectious disease dynamics. Nat Methods. 2020;17(6):557–558.
- Public Health England. National flu and COVID-19 surveillance reports: 2021 to 2022 season; 2021. Available from: https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season
- UK Health Security Agency. Antibody testing for SARS-CoV-2. Extended information for medical professionals and researchers on using and interpreting SARS-CoV-2 antibody tests; 2022. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1066325/Extended-guidance-antibody-testing.pdf
- Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK [pre-print]; 2021.
- Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK [pre-print]; medRxiv 2021. DOI:10.1101/2021.09.15.21263583
- Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against COVID-19 related symptoms and hospitalisation in England: test negative case-control study [pre-print]; medRxiv 2022. DOI:10.1101/2021.11.15.21266341
- Public Health England. PHE weekly national influenza and COVID-19 report. 16 September 2021 – week 37 report (up to week 36 data). London (UK): UK Government; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018185/Weekly_Influenza_and_COVID19_report_data_w37.xlsx
- UK Health Security Agency. COVID-19 vaccine surveillance report. Week 50. London (UK): UK Government; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1041593/Vaccine-surveillance-report-week-50.pdf
- Institute for Government Analysis. Timeline of UK Government coronavirus lockdowns and measures, March 2020 to December 2021? London (UK): Institute for Government; 2022. Available from: https://www.instituteforgovernment.org.uk/sites/default/files/timeline-coronavirus-lockdown-december-2021.pdf
- Centre for the Mathematical Modelling of Infectious Diseases (CMMID) COVID-19 Working Group, CMMID: Social contacts in the UK from the CoMix social contact survey. London (UK): UK Government; 2020.
- Jarvis CG A, Wong K, Edmunds J. Social contacts in the UK from the CoMix social contact survey. Report for survey week 89. London (UK): UK Government; 2021. Available from: https://cmmid.github.io/topics/covid19/reports/comix/Comix%20Weekly%20Report%2089.pdf
- Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–1211.
- Moore S, Hill EM, Tildesley MJ, et al. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. Lancet Infect Dis. 2021;21(6):793–802.
- Walker JL, Grint DJ, Strongman H, et al. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health. 2021;21(1):484.
- Sapey E, Gallier S, Mainey C, Nightingale P, et al. Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an urban catchment area. BMJ Open Resp Res. 2020;7:e000644.
- Mason KM, McHale P, Pennington A, et al. Age-adjusted associations between comorbidity and outcomes of COVID-19: a review of the evidence from the early stages of the pandemic. Front Public Health. 2021;9:584182.
- Castanares-Zapatero D, Kohn L, Dauvrin M, et al. Long COVID: Pathophysiology - epidemiology and patient needs – Synthesis. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2021. Available from: https://www.kce.fgov.be/sites/default/files/2021-11/KCE_344C_Long_Covid_Short_report.pdf
- Sayampanathan AA, Heng CS, Pin PH, et al. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet. 2021;397(10269):93–94.
- Sandmann FG, Davies NG, Vassall A, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021;21(7):962–974.
- Jentsch PC, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. Lancet Infect Dis. 2021;21(8):1097–1106.
- Giordano G, Colaneri M, Di Filippo A, et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nat Med. 2021;27(6):993–998.
- Li YG, Zhou Y, Cao X, et al. Toward the impact of non-pharmaceutical interventions and vaccination on the COVID-19 pandemic with time-dependent SEIR model. Front Artif Intell. 2021;4:648579.
- Hogan AB, Winskill P, Watson OJ, et al. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: a mathematical modelling analysis. Vaccine. 2021;39(22):2995–3006.
- ICNARC. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland. London (UK): ICNARC; 2021.
- Vekaria B, Overton C, Wiśniowski A, et al. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. BMC Infect Dis. 2021;21:700.
- Drummond. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
- Office for National Statistics (UK). A05 SA: Employment, unemployment and economic inactivity by age group (seasonally adjusted). In: Watson B, editor. London (UK): UK Government; 2022. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/datasets/employmentunemploymentandeconomicinactivitybyagegroupseasonallyadjusteda05sa
- Office for National Statistics (UK). Leisure time in the UK: 2015. London (UK): Office of National Statistics; 2017. Available from: https://www.ons.gov.uk/releases/leisuretimeintheuk2015
- Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 omicron VOC transmission in Danish households [pre-print]; 2021.
- Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. London (UK): UK Government; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf
- UK Health Security Agency. COVID-19 vaccine weekly surveillance reports (weeks 39 to 19, 2021 to 2022); 2022 [updated May 12, 2022]. Available from: https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
- Barnard RC, Davies NG; Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group, Jit M, Edmunds WJ. Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era [pre-print]. medRxiv. 2022;2021.11.22.21266584.
- Bosetti P, Kiem T, Andronico C, et al. Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22. Euro Surveill. 2022;27(1):2101125.
- Gavish N, Yaari R, Huppert A, et al. Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence. Sci Transl Med. 2022;14(647):eabn9836.
- Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. Int J Infect Dis. 2021;119:87–94.
- National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long term effects of COVID-19. London (UK): National Institute for Health and Care Excellence; 2022. Available from: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742
- Office for National Statistics (UK). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. London (UK): Office for National Statistics; 2021. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2december2021
- UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. London (UK): UK Health Security Agency; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043807/technical-briefing-33.pdf
- Boosters prevented over 105,000 hospitalisations, UKHSA analysis estimates [Internet]; 2022 Feb 10. Available from: https://www.gov.uk/government/news/boosters-prevented-over-105-000-hospitalisations-ukhsa-analysis-estimates#:∼:text=Vaccinations%20for%20coronavirus-,Boosters%20prevented%20over%20105%2C000%20hospitalisations%2C%20UKHSA%20analysis%20estimates,19)%20since%20mid%2DDecember
- McCabe R, Schmit N, Christen P, et al. Adapting hospital capacity to meet changing demands during the COVID-19 pandemic. BMC Med. 2020;18(1):329.
- Rocks S, Idriss O. Did hospital capacity affect mortality during the pandemic’s first wave?: the Health Foundation; 2020 [cited 2022 May 27]. Available from: https://www.health.org.uk/news-and-comment/charts-and-infographics/did-hospital-capacity-affect-mortality-during-the-pandemic
- Parker EPK, Desai S, Marti M, et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health. 2022;10(3):e326–e328.
- UK Health Security Agency. COVID-19 vaccine surveillance report. Week 19. London (UK): UK Health Security Agency; 2022. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1075115/COVID-19_vaccine_surveillance_report_12_May_2022_week_19.pdf
- Hayawi K, Shahriar S, Serhani MA, et al. Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines. 2021;9(11):1305.
- Public Health England, PHE Weekly National Influenza and COVID-19 Report. 16 September 2021 – Week 37 report (up to week 36 data). 2021. London (UK): Public Health England. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1016273/Weekly_Influenza_and_COVID19_report_data_W36.xlsx
- Wise J. Covid-19: booster doses to be offered to 30 million people in UK. BMJ. 2021;374:n2261.
- Wise J. Covid-19: UK will offer third vaccine dose to severely immunosuppressed people. BMJ. 2021;374:n2160.
- National Health Service, Who is at high risk from coronavirus (COVID-19) [Internet]; 2022 [cited 2022 May 26]. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/who-is-at-high-risk-from-coronavirus/
- Iacobucci G. Covid-19: how is the UK’s vaccine booster programme faring? BMJ. 2021;375:n2702.
- National Health Service. Hospital admitted patient care activity 2019-20. NHS Digital. 2020. London (UK): National Health Service. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2019-20/summary-reports---acc---days
- Office for National Statistics (UK). Coronavirus (COVID-19) infection survey, characteristics of people testing positive for COVID-19, UK; 2022 May 11 [updated 2022 May 11; 2022 May 25]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveycharacteristicsofpeopletestingpositiveforcovid19uk/11may2022#symptoms-profile-of-strong-positive-cases-uk
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232.
- UK Government. UK coronavirus dashboard; 2022 [cited 2022 July 27]. Available from: https://coronavirus.data.gov.uk/